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ABSTRACT: Plasmodium falciparum (Pf) prolyl-tRNA synthetase
(ProRS) is one of the few chemical-genetically validated drug targets
for malaria, yet highly selective inhibitors have not been described. In
this paper, approximately 40,000 compounds were screened to
identify compounds that selectively inhibit PfProRS enzyme activity
versus Homo sapiens (Hs) ProRS. X-ray crystallography structures
were solved for apo, as well as substrate- and inhibitor-bound forms
of PfProRS. We identiﬁed two new inhibitors of PfProRS that bind
outside the active site. These two allosteric inhibitors showed >100
times speciﬁcity for PfProRS compared to HsProRS, demonstrating
this class of compounds could overcome the toxicity related to
HsProRS inhibition by halofuginone and its analogues. Initial
medicinal chemistry was performed on one of the two compounds,
guided by the cocrystallography of the compound with PfProRS, and
the results can instruct future medicinal chemistry work to optimize these promising new leads for drug development against
malaria.
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Malaria is a devastating infection that aﬀects hundreds ofmillions of people worldwide and is concentrated in
resource-poor tropical and subtropical regions.1 Resistance has
been documented against every antiparasitic drug available,2,3
highlighting the need for new, cost-eﬀective antimalarials that
target the most deadly causative agent, Plasmodium falciparum
(Pf).
For 2000 years, the roots of blue evergreen hydrangea have
been used to treat malaria symptoms, but it was not until 1950
that the bioactive constituent responsible for fever and pain
relief was derived from the roots and identiﬁed as febrifugine
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(Figure 1).4 However, observed cytotoxicity, especially
targeting the liver, precludes the use of febrifugine as a viable
drug treatment option.5,6 During the 1960s eﬀorts by the U.S.
Army (Walter Reed Army Hospital) to develop a less toxic
alternative resulted in the synthesis of halofuginone (Figure 1),
a halogenated form of febrifugine. Although intolerable side
eﬀects of halofuginone to humans remained, it was approved
for use as an anticoccidiostat in poultry and cattle.7 It was not
until 2012 that febrifugine and halofuginone were shown to
target P. falciparum prolyl-tRNA-synthetase (PfProRS).8 Thus,
PfProRS became one of the few chemical-genetically validated
targets, but diﬃculty in deriving halofuginone for speciﬁcity of
PfProRS inhibition versus Homo sapiens (Hs)ProRS remained.
Here we report a high-throughput screen against PfProRS
and present evidence of the ﬁrst highly selective compounds
that inhibit PfProRS but not HsProRS. X-ray crystallographic
structures demonstrate that these inhibitors bind outside the
active site in an area of the enzyme that has not previously
displayed a binding pocket. The compounds act as allosteric
inhibitors through induced ﬁt into a novel pocket adjacent to
the active site.
■ RESULTS AND DISCUSSION
Recombinant Expression of PfProRS. To characterize
PfProRS in vitro, the PfProRS open reading frame (ORF)
(PF3D7_1213800) was cloned from cDNA isolated from
P. falciparum 3D7 strain. After analysis of predicted protein
structure and comparison to related structures from the ProRS
domain of human EPRS (PDB 4HVC) and the thermophilic
bacteria Methanocaldococcus jannaschii ProRS (PDB 1NJ8), we
designed four N-terminal truncations of the ORF, which we
cloned into the pBG1861 vector along with the full-length
ORF. We tested protein expression levels of the ﬁve constructs
(B1, AA1−746 (full length); B2, AA7−746 (minus 6 amino
acids, or 99% of the ORF); B3, AA224−746 (70% ORF); B4,
AA249−746 (67% ORF); B5, AA256−746 (66% ORF), Figure
S1). The full-length construct (B1) and three truncations (B2,
B4, and B5) had soluble protein expression levels suﬃcient for
puriﬁcation. Recombinant proteins were puriﬁed and analyzed
for enzyme activity and set up in crystallization experiments.
Determination of ProRS Enzymatic Activity. To assess
whether the puriﬁed protein had activity, we ﬁrst determined
the relative levels of aminoacylation activity for each of the four
soluble recombinant PfProRS proteins. Activity was measured
in an aminoacylation assay wherein radioactive proline is linked
to bulk tRNA obtained from Saccharomyces cerevisiae. We found
that all soluble recombinant proteins except the full-length
construct (B1) had enzymatic activity. Figure 2 demonstrates
the enzymatic ProRS activity for recombinant proteins B2 and
B4. Figure 2 shows the reaction dependence on S. cerevisiae
tRNA, and in experiments not shown, enzymatic activity was
also shown to be dependent on the presence of proline and
ATP. Recombinant protein B2 had only a six amino acid N-
terminal deletion compared to the full-length construct, so the
B2 puriﬁed protein was used for all additional assays, except
crystallization and structure determination, for which the B4
puriﬁed protein was used (Figure S1).
Inhibition of PfProRS Activity and Binding to PfProRS
by Halofuginone. Halofuginone is a known antimalarial and a
potent inhibitor of PfProRS.8,9 Febrifugine and derivatives,
such as halofuginone, have been shown in vivo and in vitro to
target both HsProRS and PfProRS.8,9 Halofuginone inhibition
of PfProRS was tested by an aminoacylation assay and shown
to have an IC50 of 11 nM (Figure S2). N-Boc-halofuginone
(Figure 1) was synthesized as a control and displayed <20%
inhibition of aminoacylation at the highest concentrations
tested (see also Figure S2).
Figure 1. Structures of febrifugine, halofuginone, and N-Boc-halofuginone.
Figure 2. Conﬁrmation of PfProRS activity by aminoacylation assay.
Recombinant Pf ProRS was tested for activity with increasing
concentrations of tRNA using the aminoacylation assay and 3H-
proline. Activity was dependent on bulk tRNA puriﬁed from
S. cerevisiae; bulk Escherichia coli tRNA as a substrate did not give
any signal. Controls of no tRNA and no protein gave similarly low
signal. All soluble recombinant proteins, except for the full-length B1,
gave equivalent enzymatic activity (data for B2 and B5 are not shown).
Samples were tested in triplicate, error bars indicate standard deviation
for each condition. Designation **400 is no enzyme control.
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Thermal melt analysis with recombinant protein B2 showed
a 6° shift in stability with either the cognate amino acid, proline,
or the known inhibitor, halofuginone (data not shown).
Increased stability was observed for three of the four soluble
recombinant PfProRSs. The full-length recombinant protein B1
showed no increase in stability from halofuginone. This was not
surprising because of the disordered structure suggested from
the poor melting proﬁle of B1. This disordered folding may be
due to the initial stretch of seven asparagine residues at the N-
terminus. Recombinant B2 appeared to be properly folded and
lacks only the initial seven asparagines, whereas the full-length
B1 did not appear to be folded and lacked enzyme activity.
Development of a ProRS Luminescence Assay. As
radiolabeled assays are not appropriate for high-throughput
screening (HTS), we developed and optimized an ATP
depletion luminescence assay. Reactions were incubated for 2
h at 37 °C in the presence of 60 μM proline, 3 μM ATP, and
400 μg/mL yeast tRNA. Under these conditions approximately
85% of the ATP was consumed in the positive control reactions
and consumption of ATP continued for another 2 h. The level
of ATP consumption was quantiﬁed by the addition of
luciferase (KinaseGlo, Promega, Madison, WI, USA), which
gave a luminescent signal proportional to the remaining ATP.
Luminescence is inversely related to the completion of the
enzymatic reaction. Inhibitors of luciferase would present as
false negatives and are not false positives of this screen, because
luciferase inhibitors give rise to a low luminescence signal,
whereas inhibitors of ProRS yield a high luminescence signal.
Screening Compounds for Inhibition of ProRS. We
screened 40,000 compounds in total from ﬁve compound
libraries (the SPECTRUM Microsource tested at 10 μM, the
GlaxoSmithKline Tres Cantos Antimalarial Set tested at 7.5
μM, the DDU small diversity set tested at 30 μM, the Malaria
Box tested at 10 μM, and the St. Jude Library tested at 15 μM)
for inhibition of ProRS using our ATP depletion assay. Hits
were deﬁned as having inhibition >80% or 2 standard deviation
units. Statistical analysis was performed using HutchBASE.10
Any hit above this threshold was conﬁrmed by retesting with
serial 3-fold dilutions of the compound to establish the IC50.
We identiﬁed 33 hits for which the estimated IC50 was <100
μM. For these hits, we repurchased compounds and conﬁrmed
the IC50 with a complete dose−response curve. Ten hits were
reconﬁrmed (Table S2). Finally, we counter-tested against
puriﬁed HsProRS, using the luciferase ATP depletion assay
(Table S2). Two compounds, glyburide and TCMDC-124506
(Figure 3), stood out as having inhibitory activity (IC50) against
PfProRS at 34 μM and 74 μM, respectively, but <40%
inhibitory activity for HsProRS up to the limit of solubility (>1
mM). This is in contrast to halofuginone, which showed IC50
values for PfProRS (IC50 = 275 nM) and HsProRS (IC50 = 2
μM) within 8-fold of one another (Figure 4).
Structure Determination. Three-dimensional structural
modeling provides insight into areas of the ProRS enzyme that
can be exploited for drug development. HsProRS structures
were recently solved for both the apo form and the form bound
to halofuginone.11,12 The structure of cytoplasmic PfProRS
bound to halofuginone has been solved both by our team and
independently by another group.13 The crystal structure
indicates that the B4 recombinant PfProRS protein forms a
dimer, which is further supported by the sieving properties
observed through a size exclusion column. There is a
disordered loop that folds over the binding site that is poorly
resolved, but may provide a promising site for optimizing
speciﬁc binding of halofuginone Pf ProRS compared to
HsProRS. Halofuginone sits in the active site pocket and can
be competitively removed by the addition of excess proline.
The PfProRS has striking similarity to the HsProRS orthologue.
There is >66% amino acid similarity between PfProRS and
HsProRS. One hundred percent identity was observed
throughout the binding residues for halofuginone.13 This
suggests that achieving speciﬁcity for binding of halofuginone
analogues to PfProRS compared to HsProRS would be diﬃcult.
On the basis of the results of our compound library screening
and identiﬁcation of their high aﬃnity for PfProRS, glyburide
and TCMDC-124506 were used in cocrystallization trials with
PfProRS. The compounds are diverse in structure, but share a
common urea core, bracketed on each side by a six-membered
ring (head) and a longer tail (Figure 3). We determined the
structure of PfProRS with glyburide to 2.45 Å and that of
PfProRS with TCMDC-124506 to 1.65 Å. Surprisingly, these
compounds did not bind in the known active site, neither
where the nucleotide nor where halofuginone binds (Figure
5A). Instead, both compounds bound adjacent to the ATP
binding site in a pocket formed by α9 (residues 261−272), α5
(residues 513−524), β-hairpin β1-β2 (residues 276−287), and
α2 (residues 261−272) (Figure 5B,C). Both compounds bind
in a similar fashion, within space normally occupied by the
hairpinned end of the loop between residues 389 and 404. In
both structures no density was observed for most of this loop.
The headgroup of each compound sits in a hydrophobic pocket
normally occupied by Phe399 (Figure 7B). Phe399 lies within
the hairpin loop that is displaced upon compound binding. The
urea group from each compound makes hydrogen bonds to
Glu404 and Tyr266 (Figure 6). For both compounds, these are
strong hydrogen bonds made between the compound and
protein. Moving beyond the head and urea components, the
compounds diﬀer in the binding of the tail. TCMDC-124506’s
tail occupies the cavity by making hydrophobic interactions
with the surrounding residues (Figure 6A). Glyburide’s tail
extends through the length of the same cavity to the solvent,
predominately making hydrophobic interactions with surround-
ing residues Tyr266, Arg514, Tyr746, Ser263, and Asn470.
There is also a weak hydrogen bond between Arg514 and the
sulfoxide group of glyburide (Figure 6B).
ProRS Function Is Inhibited by ATP Binding Site
Distortion. The binding of both glyburide and TCMDC-
124506 into the novel binding site signiﬁcantly distorts the
nucleotide binding site (Figure 7). Here we compare the
nucleotide binding site observed in the halofuginone/AMPPNP
Figure 3. Structures of PfProRS inhibitors glyburide and TCMDC-
124506 found by HTS.
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bound structure (green) to the glyburide (blue) and TCMDC-
124506 (orange) structures. Movement of the loop between
residues 389 and 404 displaces several key residues that
participate in nucleotide binding: Phe405 (which forms pi−pi
stacking interactions with the adenosine ring), Arg390 (which
hydrogen bonds to the α and β phosphates), and Arg401
(which hydrogen bonds to the γ phosphate). Although Arg390
and Arg401 were not seen in the electron densities in either the
glyburide or TCMDC-124506 structures, we can hypothesize
their approximate positions on the basis of the displacement of
their adjacent residues. Additionally, the movement of this loop
condenses the nucleotide binding site. We hypothesize that it is
the presence of the hydrophobic headgroup in glyburide and
TCMDC-124506 that initially brings the compound into this
adjacent binding site. It is then the urea group that draws
Glu404 toward it, which ratchets the side chain around and
draws the C-terminal half of this loop into the nucleotide
binding site, which then causes residues important to
nucleotide binding to be signiﬁcantly shifted. To elaborate on
these compounds for higher aﬃnity, the head and urea portions
of the compounds should be retained and the tails manipulated
to further exploit this new binding site, causing distortion to the
nucleotide binding site. This novel scaﬀold and binding site
provide a new basis for structure-based drug design as these
compounds are not based on halofuginone and, unlike
halofuginone, are nucleotide-independent binders.
Pyrazolo Urea Analogues of TCMDC-124506. Pyrazolo
urea TCMDC-124506 shows low micromolar inhibition of
Figure 4. PfProRS inhibition dose response: inhibition of PfProRS enzyme activity at various concentrations of glyburide (blue), halofuginone
(green), and TCMDC-124506 (orange). Lines are ﬁtted to Hill equation with a slope = 1, and the calculated IC50 values for the compounds in this
assay are PfProRS for 34 μM glyburide, 0.28 μM halofuginone, and 73 μM TCMDC-124506 and HsProRS for >700 μM glyburide, 2.13 μM
halofuginone, and >700 μM TCMDC-124506. Compounds were counter-screened against HsProRS to determine speciﬁcity. Enzyme activity was
determined by luciferase ATP depletion assay (75 nM ProRS enzyme, 60 μM proline, 6 μM ATP, and 400 μg/mL yeast tRNA were incubated for 2
h at 37 °C). Inhibition values shown on the graph are the average of three data points.
Figure 5. Structures of halofuginone and AMPPNP, TCMDC-124506, or glyburide bound to PfProRS: (A) structures of halofuginone and
AMPPNP bound to PfProRS (green), TCMDC-124506 bound to PfProRS (orange), and glyburide bound to PfProRS (blue); (B) magniﬁcation of
the TCMDC-124506 binding site indicating key polar interactions with the pocket surface in gray; (C) magniﬁcation of the glyburide binding site
indicating key polar interactions with the pocket surface in gray.
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PfProRS in the ATP consumption assay and selectivity over
HsProRS. Additionally, good cellular selectivity is also
demonstrated for Pf (3D7) (EC50 = 0.6 μM) over a mammalian
cell line (HsHEPG2, EC50 > 50 μM) (data not shown). In
addition to its activity and selectivity, it has good
physicochemical and DMPK properties. It has physicochemical
properties consistent with oral drug-space, with a molecular
weight below 400 (MW 396) and logP 4.4. Moreover, the
experimental logD is <3 (CHI-logD 2.9), kinetic solubility is
good (>250 μM), and mouse microsomal clearance is moderate
(Cli = 1.6 mL/min/g).
The parasite-killing activity of TCMDC-124506 (Table 1) is
greater than the compound’s activity against PfProRS. Similar
pyrazolo amides and ureas have been reported to target the P-
Figure 6. Key PfProRS residues that complex with TCMDC-124506 (A, orange) and glyburide (B, blue).
Figure 7. Binding of TCMDC-124506 and glyburide to PfProRS. (A) The binding of TCMDC-124506 (orange) or glyburide (blue) displaces the
PfProRS TXE-Loop from a conserved conformation seen in liganded and unliganded structures of both HsProRS (4HVC (magenta), 4K86 (pink),
4K87(red), 4K88 (maroon)) and PfProRS (4OLF (green), 4TWA (yellow), and 4YDQ (teal)). (B) The TXE-Loop in AMPPNP and halofuginone
bound PfProRS (green) forms interacts in the TCMDC-124506 and glyburide binding site and interacts tightly with the ATP mimic. The binding of
TCMDC-124506 (orange) or glyburide (blue) in the novel binding site signiﬁcantly distorts the conformation of the TXE-Loop, disrupting key
interactions between ATP and PfProRS.
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type cation-ATPase PfATP4,14 which has been proposed to
extrude Na+ ions from the parasite while importing H+ ions.15
TCMDC-124506 was tested in Na+ and pH assays15,16 in
P. falciparum. The compound at (when tested at 1 μM) caused
the Na+ concentration in the parasite cytosol to increase in the
same manner as that seen for a supramaximal concentration (50
nM) of the spiroindolone KAE609,17 which is believed to target
PfATP415 (Figure S3). As seen for other compounds that have
been proposed to exert their antiplasmodial eﬀects through
inhibition of PfATP4,14−16 TCMDC-124506 caused an increase
in the parasite cytosolic pH and a reduction in the degree of
acidiﬁcation observed following inhibition of the parasite’s V-
type H+ pump with concanamycin A (Figure S3). The
antiplasmodial activity of TCMDC-124506 is therefore likely
to be attributable to inhibition of PfATP4 rather than inhibition
of PfProRS. The lack of correlation between the EC50s for Pf
(3D7) growth inhibition and the IC50s for PfProRS inhibition
seen for TCMDC-124506 and its analogues (Table 1) provide
further evidence that the compounds do not kill parasites via
inhibition of PfProRS.
Analogues of TCMDC-124506 were designed, guided by the
cocrystal structure with PfProRS, with the aim of increasing
binding aﬃnity for PfProRS and potency against Plasmodium.
The compound IC50 values against PfProRS enzyme activity
were determined by an ATP consumption assay slightly
modiﬁed from the screening assay. The screening assay was
conducted at a higher temperature and with a higher ATP
concentration. Inhibition values were determined in the linear
range of the assay, such that comparative IC50 values could be
reliably measured. ATP and proline compete with TCMDC-
124506 for binding (Supporting Information Figure S4) such
that higher substrate concentrations yield higher IC50 values.
The diﬀerences in the two assays explain the diﬀerence in the
TCMDC-124506 IC50 values determined with the screening
Table 1. Activity of TCMDC-124506 and Analogues
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assay in Figure 4 versus the lower IC50 determined in Table 1,
the latter of which was conducted at lower ATP concentrations.
The crystal structure showed that the urea moiety (R4) forms
multiple H-bonds with the protein and the aromatic
substituents at R4 ﬁt into a hydrophobic pocket (see Table 1
for deﬁnitions of R1, R2, R3, and R4) and, in fact, removal of the
urea (2) led to an inactive compound. The o,p-diF-substituted
phenyl urea derivative (3) retained activity and the m-F
substitution on the phenyl ring (4) was tolerated, whereas any
other modiﬁcation around this moiety (see as representative
compounds 5 and 6) proved to be detrimental for PfProRS
activity. Analysis of the costructure suggested that the
displacement of structural water molecules could be achieved
by the addition of hydrogen bond acceptors/donors at R1 and
R3. Additional expansion to solvent from the R2 (CF3) vector
could be used to improve the physicochemical properties of the
molecule.
Removal of the R1 pyrazole N-methyl group (7) was not
tolerated, leading to an inactive compound. Addition of polar
groups with H-bond donors and acceptors (8 and 9) to address
Tyr278, Arg403, or Tyr285 was also detrimental for activity
(Table 1).
Removal of the p-F-phenyl substituent at R3 (10) or
replacement of a bromine (11) led to inactive compounds.
Addition of a ﬂuorine atom at the meta position (12) was not
tolerated by the enzyme. A water molecule interacting with
Glu404 and Arg514 was targeted for replacement, but failed to
increase potency. The introduction of a benzylic alcohol at the
ortho position of the aromatic ring (13) led to a small (4-fold)
drop in potency. Extending the linker to the alcohol from one
to two carbons (14) was not tolerated. Moving this
hydroxyethyl substituent to a meta position (15) led to a
compound with activity similar to that of the hit compound.
However, a mesylated benzylic amine (16) was inactive. Finally,
m-CF3-phenyl (17) substituent at R
3 was also detrimental for
PfProRS inhibition (Table 1).
The R2 (CF3) vector points to solvent, and a diversity of
polar and basic groups were tested. Removal of the CF3 group
(18) was not tolerated. When the CF3 group was replaced by
an alcohol (19), a drop in potency was observed. Introduction
of primary amides with one (20) and two carbon linkers (21)
was tolerated. Modeling showed that amide 21 could interact
favorably with Tyr746, and this compound shows levels of
PfProRS inhibition similar to that of the initial hit. Nitriles
directly linked to the pyrazole (22) and with one carbon (23)
and two carbon linkers (24) all inhibit the enzyme in the low
micromolar range. Finally, the introduction of basic sub-
stituents at R2 (25 and 26) led to the best results in terms of
PfProRS inhibition. The medicinal chemistry results described
above and the cocrystallography results can help guide future
medicinal chemistry approaches to optimize the allosteric hits
to a lead for malaria therapy (Figure 8).
Summary of Findings and Signiﬁcance. New drugs for
malaria are urgently needed due to emerging resistance to
artemisinin combination therapy.18 There is a dearth of
structural information available on potential drug targets within
the organism. PfProRS is a promising new target that is
chemically and genetically validated by halofuginone, a
synthetic derivative of the natural product febrifugine which
has been known for more than 2000 years to possess
antimalarial activity.9 However, halofuginone is also a potent
inhibitor of HsProRS, which leads to toxicity when human
patients are treated.
We have solved the three-dimensional structure of PfProRS,
with and without halofuginone. The overlaid structures of
PfProRS and HsProRS suggest that biologically it could be
diﬃcult to achieve speciﬁcity with halofuginone and that
halofuginone represents a poor starting point, as the residues
binding halofuginone in the active site are identical in PfProRS
and HsProRS.
As expected, increasing proline concentrations reduce the
inhibition of halofuginone, because halofuginone binds in the
area that proline occupies in the active site. Interestingly,
increasing ATP concentrations have the opposite eﬀect, and
halofuginone becomes more inhibitory at higher concentrations
of ATP. One explanation for this observation is that higher
ATP concentrations increase the consumption of proline and
charges the tRNA, leaving the proline binding pocket accessible
for halofuginone to bind, subsequently replacing proline.
Another possibility is that ATP binding of PfProRS induces a
change in the halofuginone binding site, increasing halofugi-
none’s aﬃnity for PfProRS.
TCMDC-124506 was identiﬁed as a PfProRS inhibitor. The
eﬀect on inhibition of PfProRS by this compound was
evaluated when the concentrations of proline and ATP were
varied (Supporting Information Figure S4). For TCMDC-
124506 an increase in IC50 for PfProRS inhibition was
observed as the ATP or proline concentration was increased
was found. Thus, the inhibitory eﬀect of TCMDC-124506 was
reduced by increasing concentrations of ATP or proline, but it
was not as marked an eﬀect as for halofuginone. This suggests
that proline and ATP binding changes the loop structure of the
protein above and adjacent to the active site, making it less
accessible for binding of TCMDC-124506. We conclude that
TCMDC-124506 is a competitive allosteric inhibitor, because
ATP and proline substrates both compete for TCMDC-124506
Figure 8. Structure−activity relationship of TCMDC-124506 analogues.
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binding, but yet the TCMDC-124506 binding occurs outside
the active site. This also suggests that the parasite could become
more resistant to the eﬀects of such an inhibitor by increasing
its intracellular concentration of proline, which would be a
potential liability. Indeed, this mechanism of resistance to
halofuginone analogues, accomplished by the parasite increas-
ing its intracellular proline levels, was described by Hermann et
al.9
We synthesized a limited series of variants to TCMDC-
124506 to attempt to ﬁnd more potent inhibitors while
retaining speciﬁcity. Our initial exploration, detailed above and
in Table 1, was unsuccessful in improving potency. However,
we hope that the detailed structure of TCMDC-124506 and
glyburide binding to PfProRS will encourage others to explore
this allosteric pocket in more detail and consider making
additional analogues of these inhibitors. Indeed, many more
analogues can be envisioned that will ﬁt in the pocket, and it is
likely the pocket can move to accommodate additional
structural diversity, strengthen interactions with the protein,
and improve the potency of the inhibitor. It is possible that
further high-throughput screening combined with structure
determination will lead to new chemical leads or further
elaboration of TCMDC-124506 and glyburide.
■ METHODS
Pf and Hs ProRS Cloning. Recombinant PfProRS was
generated using methods described previously.19 The PfProRS
sequence was PCR-ampliﬁed from P. falciparum 3D7 cDNA;
speciﬁc primer sequences for each construct are provided in
Supporting Information Table S1. Preparative gel electro-
phoresis was used to isolate the desired band, which was
subsequently excised and puriﬁed using a gel extraction kit
(Zymoresearch, Irvine, CA, USA). The puriﬁed PCR product
was treated with T4 DNA polymerase (NEB, Ipswich, MA,
USA) for ligation-independent cloning (LIC) and annealed to a
LIC prepared BG1861 vector, which contains a T7 promoter
and a noncleavable N-terminal hexahistidine (6×His) nickel-
aﬃnity tag. Puriﬁed plasmids were transformed into BL21-
(DE3)R3 Rosetta Oxford chemically competent E. coli
expression strain and screened for expression.
Pf and Hs ProRS Upscale. Starter cultures of PA-0.5G
noninducing media with appropriate antibiotics were grown for
18 h at 25 °C.20 Antibiotics were added to 2 L bottles of sterile
ZYP-5052 autoinduction media, and the bottles were
inoculated with overnight cultures. Inoculated bottles were
then placed into a LEX bioreactor and cultures grown for 72 h
at 20 °C. To harvest, the medium was centrifuged at 6000 RCF
for 30 min at 4 °C. Cell paste was frozen and stored at −80 °C
prior to puriﬁcation.
Pf and Hs ProRS Puriﬁcation. Frozen cells were
resuspended in lysis buﬀer (25 mM HEPES (pH 7.0), 500
mM NaCl, 5% (v/v) glycerol, 30 mM imidazole, 0.025% (w/v)
sodium azide, 0.5% (w/v) CHAPS, 10 mM MgCl2, 1 mM
TCEP, 250 ng/mL AEBSF, and 0.05 μg/mL lysozyme) and
disrupted on ice for 30 min with a Virtis sonicator using
alternating on/oﬀ cycles of 15 s. Cell debris was incubated with
20 μL of benzonase nuclease (25 U/mL) at room temperature
for 45 min and clariﬁed by centrifugation on a Sorvall SLA-
1500 at 30,000 RCF for 60 min at 4 °C. Protein for X-ray
crystallography was puriﬁed from clariﬁed cell lysate by
immobilized metal aﬃnity chromatography. A His Trap FF 5
mL column (GE Healthcare) was equilibrated with binding
buﬀer (25 mM HEPES (pH 7.0), 500 mM NaCl, 5% (v/v)
glycerol, 30 mM imidazole, 0.025% (w/v) sodium azide, 1 mM
Table 2. Structural Data Statistics
crystal apo halofuginone AMPPNP TCMDC-124506 glyburide
PDB code 4NCX 4Q15 4WI1 5IFU
Data collection
resolution range (Å) 50.00−1.85 50.00−2.35 50.00−1.65 50.00−2.45
(1.90−1.85) (2.41−2.35) (1.69−1.65) (2.51−2.45)
space group C2 P212121 C2 P43212
unit cell dimensions 147.96, 91.38, 110.84 76.58, 78.09, 167.82 148.18, 91.34, 110.91 138.31, 138.31, 156.66
90.00, 129.48, 90.00 90.00, 90.00, 90.00 90.00, 129.53, 90.00 90.00, 90.00, 90.00
no. of unique reﬂections 96638 42603 133468 56139
Rmerge (%)
a 4.9 (49.1) 6.4 (54.7) 4.9 (53.9) 6.6 (53.3)
redudancy 4.5 (4.6) 5.1 (5.3) 4.2 (4.3) 7.3 (7.5)
completeness (%) 99.2 (99.2) 99.6 (99.9) 97.2 (96.2) 99.5 (100.0)
l/σI 19.36 (3.11) 19.82 (3.24) 16.31 (3.07) 18.69 (4.15)
Reﬁnement
resolution range 50.00−1.85 50.00−2.35 50.00−1.65 50.00−2.45
(1.90−1.85) (2.41−2.35) (1.69−1.65) (2.51−2.45)
no. of protein atoms 7084 7190 7203 6942
no. of water molecules 603 273 765 243
Rcryst (%) 16.9 19.5 16.2 18.5
Rfree (%) 20.6 20.9 18.8 21.3
Root-mean-square deviations from ideal stereochemistry
bond lengths (Å) 0.013 0.003 0.007 0.003
bond angles (deg) 1.511 0.757 1.047 0.668
mean B factor (all atoms) (Å2) 33.04 44.51 33.27 61.33
Ramachandran plot
favored region (%) 97.08 96.90 97.79 96.74
allowed regions (%) 2.56 2.99 2.08 2.56
outlier regions (%) 0.37 0.11 0.12 0.70
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TCEP). The protein was eluted in the same buﬀer with 250
mM imidazole added. Size exclusion chromatography (SEC)
was done using a HiLoad 26/60 Superdex 75 column (GE
Healthcare) equilibrated in SEC buﬀer (20 mM HEPES (pH
7.0), 300 mM NaCl, 2 mM DTT, and 5% (v/v) glycerol). Pure
fractions were collected and pooled from a single peak in the
chromatogram and concentrated using Amicon Ultra centrifu-
gal ﬁlters. The ﬁnal protein was concentrated to approximately
25 mg/mL, aliquoted into 100 μL tubes, ﬂash frozen in liquid
nitrogen, and stored at −80°C.
Crystallography and Structure Determination. ProRS
concentration was adjusted to 20−25 mg/mL and incubated
with either 5 mM L-proline and ATP; 4 mM halofuginone,
AMPPNP, MgCl2, and β-mercaptoethanol; 5 mM TCMDC-
124506; or 5 mM glyburide for 5 min at 289 K. Crystals were
then grown at 289 K by sitting drop vapor diﬀusion with 0.4 μL
of protein/ligand complex mixed with 0.4 μL of reservoir
solution. Each reservoir solution diﬀered. For apo crystals the
reservoir solution was 10% PEG-800, 20% ethylene glycol, 0.1
M MES/imidazole, pH 6.5, and 0.03 M each sodium ﬂuoride,
sodium bromide, and sodium iodide. For halofuginone/
AMPPNP crystals the reservoir solution was 20% PEG-2000
MME and 0.1 M Tris base/HCl, pH 7.0. For TCMDC-124506
crystals the reservoir solution was 10% PEG-800, 20% ethylene
glycol, 0.1 M MES/imidazole, pH 6.5, and 0.03 M each
magnesium chloride and calcium chloride. For glyburide
crystals the reservoir solution was 10% PEG-800, 20% ethylene
glycol, 0.1 M MES/imidazole, pH 6.5, and 0.02 M each sodium
formate, ammonium acetate, trisodium citrate, sodium
potassium tartrate, and sodium oxamate. All crystals were
harvested directly into liquid nitrogen without cryoprotection
except for halofuginone/AMPPNP crystals, which were cryo-
protected in a solution containing 80% reservoir solution and
20% ethylene glycol supplemented with both halofuginone and
AMPPNP.
Data for apo PfProRS were collected at 100 K on a
Marmosaic 225 mm CCD detector at a wavelength of 0.9786 Å
on beamline 21-ID-F at the Advanced Photon Source (APS,
Argonne, IL, USA). Data for PfProRS with halofuginone/
AMPPNP were collected at 100 K on a Marmosaic 300 mm
CCD detector at a wavelength of 0.9786 Å on beamline 21-ID-
G at the Advanced Photon Source. Data for PfProRS with
TCMDC-124506 and PfProRS with glyburide were collected at
100 K on a Rayonix MX-225 detector at a wavelength of 0.9795
Å on beamline 08ID-1 at the Canadian Light Source (CLS,
Saskatoon, SK, Canada). For all data sets, indexing and
integration were carried out using XDS and the scaling of the
intensity data was accomplished with XSCALE.21 For apo
PfProRS, the structure was solved using molecular replacement
with Phaser with 4HVC as a starting model.22 All subsequent
structures were solved using Fourier synthesis with Refmac5
with the previously solved PfProRS structure providing the
phases.23 For the apo PfProRS structure, reﬁnement was
carried out using Refmac5, TLS, and manual reﬁnement in
Coot.24,25 For all subsequent structures reﬁnement was carried
out with Phenix in place of Refmac.26 All structures were
quality checked by Molprobity.27 Data statistics and reﬁnement
are given in Table 2 and deposited to the PDB (PDB IDs:
4NCX, 4Q15, 4WI1, 5IFU).
Compound Libraries for Screening. SPECTRUM
Microsource targeted diversity library (2320 compounds) is a
commercially available library composed of drug-like compo-
nents, natural products, and bioactive components. Com-
pounds were tested at a single concentration of 10 μM.
GlaxoSmithKline (GSK) Tres Cantos Antimalarial Set
(TCAMS) is a collection of 13,533 conﬁrmed inhibitors of
P. falciparum cell growth, selected from over 2 million
compounds from GSK’s chemical library.28 These compounds
have been conﬁrmed to inhibit parasite growth by at least 80%
at 2 μM and have antiplasmoidal activity while not inhibiting
human cell lines by >20%. The TCAMS compounds were
tested at a single concentration of 7.5 μM. The DDU small
diversity library composed of 15,667 compounds was tested at
30 μM. The St. Jude Library (gift of Dr. Kip Guy) is a
collection of 7798 compounds;29 these were tested at 15 μM.
The MMV Malaria Box compounds are a 400 compound
subset of the TCAMS, Novartis, and St. Jude’s 14,000
compound hits (http://www.mmv.org/malariabox).
Enzyme Assays. Two diﬀerent enzyme assays were
employed: the aminoacylation of tRNA measuring the
conjugation of radioactive proline to tRNA and the
consumption of ATP and measurement of ATP consumption
in the full reaction using luciferase and KinaseGlo reagent.
The method for the aminoacylation assay employed 10 nM
PfProRS enzyme, 100 nM [3H]-L-proline (PerkinElmer), 100
μM ATP (Sigma), and 400 μg/mL S. cerevisiae tRNA (Sigma,
R4251) with an incubation for 2 h at 25 °C. At the end of 2 h,
the macromolecules including tRNAs precipitated with 10%
trichloroacetic acid (Fisher Scientiﬁc), and precipitates were
collected in 96-well ﬁlter plates (Millipore MSHVN4B10).
Enzyme PfProRS B2 with truncation of the N-terminal six
amino acids was employed for most experiments, although B4
truncation enzyme was used as well in Figure 2. Triplicate
values were determined, and the standard error was calculated
and displayed.
The ATP consumption assay was run in two diﬀerent
formats. For the HTS, the assay was run with 75 nM PfProRS
A2 enzyme, 60 μM proline, 6 μM ATP, and 400 μg/mL yeast
tRNA and incubated for 2 h at 37 °C. The signal-to-noise was
>10-fold, and the Z′ of the assay was ≥0.67. This assay was also
run for Figure 4, but 75 nM human ProRS was included for
some of the measurements. Note that consumption of ATP
continued for another hour in this assay for both enzymes, so
the relative IC50 values determined in Figure 4 are signiﬁcant,
although the absolute IC50 values of compounds diﬀer from the
modiﬁed ATP consumption assay. The modiﬁed ATP
consumption assay was in the linear part of the consumption
curve for comparing IC50 values reported in Table 1. These
conditions were 75 nM ProRS A2 enzyme, 60 μM proline, 4
μM ATP, and 400 μg/mL yeast tRNA and incubated for 3.5 h
at 20 °C. The conditions were found to be linear up to 5 h, and
measuring the IC50 of halofuginone at diﬀerent time points in
the assay (3, 4, and 5 h) gave IC50 values with <2-fold variation,
which is within experimental error. The signal-to-noise of this
assay was >5-fold, with Z′ > 0.55.
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